KR20030016298A - 칸디다증의 치료를 위한 조성물 및 방법 - Google Patents
칸디다증의 치료를 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20030016298A KR20030016298A KR1020027017318A KR20027017318A KR20030016298A KR 20030016298 A KR20030016298 A KR 20030016298A KR 1020027017318 A KR1020027017318 A KR 1020027017318A KR 20027017318 A KR20027017318 A KR 20027017318A KR 20030016298 A KR20030016298 A KR 20030016298A
- Authority
- KR
- South Korea
- Prior art keywords
- mice
- albicans
- candida albicans
- adjuvant
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000222122 Candida albicans Species 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 30
- 201000003984 candidiasis Diseases 0.000 title abstract description 16
- 206010007134 Candida infections Diseases 0.000 title abstract description 12
- 229960005486 vaccine Drugs 0.000 claims abstract description 30
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims description 59
- 108090000978 Interleukin-4 Proteins 0.000 claims description 45
- 210000004027 cell Anatomy 0.000 claims description 39
- 102100037850 Interferon gamma Human genes 0.000 claims description 37
- 108010074328 Interferon-gamma Proteins 0.000 claims description 37
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 229940095731 candida albicans Drugs 0.000 claims description 31
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 22
- 102000013462 Interleukin-12 Human genes 0.000 claims description 16
- 108010065805 Interleukin-12 Proteins 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 15
- 210000001165 lymph node Anatomy 0.000 claims description 10
- 210000003296 saliva Anatomy 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 10
- 238000005259 measurement Methods 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 7
- 201000010927 Mucositis Diseases 0.000 claims description 7
- 230000000306 recurrent effect Effects 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 208000003265 stomatitis Diseases 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 4
- 230000002085 persistent effect Effects 0.000 claims description 4
- 206010030216 Oesophagitis Diseases 0.000 claims description 3
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims description 3
- 208000006881 esophagitis Diseases 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 238000010172 mouse model Methods 0.000 claims description 3
- 210000001635 urinary tract Anatomy 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 210000001989 nasopharynx Anatomy 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229940124856 vaccine component Drugs 0.000 claims 1
- 229940126578 oral vaccine Drugs 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 137
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 50
- 102000004388 Interleukin-4 Human genes 0.000 description 41
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 28
- 210000001744 T-lymphocyte Anatomy 0.000 description 27
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 238000002649 immunization Methods 0.000 description 17
- 230000003053 immunization Effects 0.000 description 17
- 210000000214 mouth Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 208000007027 Oral Candidiasis Diseases 0.000 description 15
- 210000002200 mouth mucosa Anatomy 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 13
- 230000009885 systemic effect Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 9
- 206010048685 Oral infection Diseases 0.000 description 8
- 230000003111 delayed effect Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 210000005253 yeast cell Anatomy 0.000 description 8
- 240000001046 Lactobacillus acidophilus Species 0.000 description 6
- 206010042938 Systemic candida Diseases 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 206010017938 Gastrointestinal candidiasis Diseases 0.000 description 5
- 230000009696 proliferative response Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000287411 Turdidae Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000017307 interleukin-4 production Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000012449 sabouraud dextrose agar Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010065764 Mucosal infection Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- 208000036732 invasive candidiasis Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003618 borate buffered saline Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000004264 complement component 5 deficiency Diseases 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000584 environmental toxicity Toxicity 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ8214 | 2000-06-19 | ||
| AUPQ8214A AUPQ821400A0 (en) | 2000-06-19 | 2000-06-19 | Composition and methods for treatment of candidiasis |
| AUPQ8294A AUPQ829400A0 (en) | 2000-06-22 | 2000-06-22 | Compositions and methods for treatment of candidiasis |
| AUPQ8294 | 2000-06-22 | ||
| PCT/AU2001/000725 WO2001097836A1 (en) | 2000-06-19 | 2001-06-19 | Compositions and methods for treatment of candidiasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030016298A true KR20030016298A (ko) | 2003-02-26 |
Family
ID=25646360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027017318A Withdrawn KR20030016298A (ko) | 2000-06-19 | 2001-06-19 | 칸디다증의 치료를 위한 조성물 및 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7655248B2 (https=) |
| EP (1) | EP1303300B1 (https=) |
| JP (1) | JP4933714B2 (https=) |
| KR (1) | KR20030016298A (https=) |
| CN (2) | CN1443075A (https=) |
| AT (1) | ATE476987T1 (https=) |
| BR (1) | BR0111785A (https=) |
| CA (1) | CA2411912C (https=) |
| DE (1) | DE60142786D1 (https=) |
| WO (1) | WO2001097836A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6146411A (en) * | 1998-12-24 | 2000-11-14 | Alsius Corporation | Cooling system for indwelling heat exchange catheter |
| AUPQ761200A0 (en) * | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
| CA2577165C (en) * | 2004-08-17 | 2015-01-27 | Hunter Immunology Pty Limited | Oral killed vaccines and method for providing same |
| EP1723965A1 (en) | 2005-05-18 | 2006-11-22 | Stallergenes Sa | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
| WO2009013972A1 (ja) * | 2007-07-24 | 2009-01-29 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | 免疫アジュバント及びＩｇＡ抗体測定方法 |
| US9180173B2 (en) * | 2013-12-09 | 2015-11-10 | Stephanie D. Neider | Methods of treating psoriasis using candida antigen |
| FR3048361B1 (fr) * | 2016-03-01 | 2020-12-18 | Biose | Compositions pour le traitement des candidoses |
| CN106635849A (zh) * | 2016-11-15 | 2017-05-10 | 河北工程大学 | 一种白色念珠菌感染鸡模型建立的方法 |
| US11273190B2 (en) * | 2019-05-06 | 2022-03-15 | Kenda Rigdon | Composition of heat-killed yeast and taurine or a phytomedicine for the treatment of chronic inflammation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2397839A1 (fr) * | 1977-07-18 | 1979-02-16 | Grimberg Georges | Compose donnant un vaccin oral intestinal |
| CH680192A5 (https=) * | 1989-12-13 | 1992-07-15 | Nestle Sa | |
| JP3510639B2 (ja) * | 1991-06-28 | 2004-03-29 | カルピス株式会社 | インターロイキン産生能を調節する機能を持たせた機能性食品又は健康食品 |
| GB9417880D0 (en) * | 1994-09-06 | 1994-10-26 | Auspharm Int Ltd | Vaccine |
| US5811249A (en) * | 1994-10-21 | 1998-09-22 | University Of Utah Research Foundation | Control of infectious microorganisms by modulation of chorionic gonadotropin-related protein activity |
| US5661377A (en) | 1995-02-17 | 1997-08-26 | Intraop Medical, Inc. | Microwave power control apparatus for linear accelerator using hybrid junctions |
| JPH09110707A (ja) * | 1995-10-12 | 1997-04-28 | Wakamoto Pharmaceut Co Ltd | 慢性腎不全改善剤および透析患者のクオリティー オブ ライフ改善剤 |
| US5902578A (en) * | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
| US5858378A (en) * | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| EP0834322A3 (en) * | 1996-10-04 | 1998-04-22 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Mycosis vaccine |
| JPH10139674A (ja) * | 1996-11-11 | 1998-05-26 | Yakult Honsha Co Ltd | インターロイキン１２産生促進剤 |
| US5869290A (en) * | 1996-11-21 | 1999-02-09 | Smithkline Beecham Corporation | Cayae1 polynucleotides |
| WO1999017788A1 (en) * | 1997-10-06 | 1999-04-15 | Abbott Laboratories | Composition of treatment of candidiasis |
| ATE207755T1 (de) * | 1998-04-30 | 2001-11-15 | Vesely Renata Maria Cavaliere | Pharmazeutische zusammensetzungen enthaltend lactobacillus brevis und lactobacillus salivarius zur behandlung von vaginainfektionen |
| US20020009429A1 (en) * | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
-
2001
- 2001-06-19 DE DE60142786T patent/DE60142786D1/de not_active Expired - Lifetime
- 2001-06-19 BR BR0111785-8A patent/BR0111785A/pt not_active Application Discontinuation
- 2001-06-19 EP EP01942899A patent/EP1303300B1/en not_active Expired - Lifetime
- 2001-06-19 AT AT01942899T patent/ATE476987T1/de not_active IP Right Cessation
- 2001-06-19 CN CN01812991A patent/CN1443075A/zh active Pending
- 2001-06-19 CN CN201010200300A patent/CN101862449A/zh active Pending
- 2001-06-19 KR KR1020027017318A patent/KR20030016298A/ko not_active Withdrawn
- 2001-06-19 US US10/311,837 patent/US7655248B2/en not_active Expired - Fee Related
- 2001-06-19 CA CA2411912A patent/CA2411912C/en not_active Expired - Lifetime
- 2001-06-19 WO PCT/AU2001/000725 patent/WO2001097836A1/en not_active Ceased
- 2001-06-19 JP JP2002503320A patent/JP4933714B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101862449A (zh) | 2010-10-20 |
| WO2001097836A1 (en) | 2001-12-27 |
| CA2411912A1 (en) | 2001-12-27 |
| EP1303300A1 (en) | 2003-04-23 |
| US20040037854A1 (en) | 2004-02-26 |
| EP1303300B1 (en) | 2010-08-11 |
| ATE476987T1 (de) | 2010-08-15 |
| EP1303300A4 (en) | 2004-03-24 |
| CN1443075A (zh) | 2003-09-17 |
| US7655248B2 (en) | 2010-02-02 |
| CA2411912C (en) | 2014-06-17 |
| DE60142786D1 (de) | 2010-09-23 |
| BR0111785A (pt) | 2003-05-20 |
| JP4933714B2 (ja) | 2012-05-16 |
| JP2004502653A (ja) | 2004-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7797208B2 (ja) | プレボテラ（Ｐｒｅｖｏｔｅｌｌａ）を使用してＴＨ２媒介性状態を処置する組成物及び方法 | |
| Elahi et al. | Enhanced clearance of Candida albicans from the oral cavities of mice following oral administration of Lactobacillus acidophilus | |
| JP2020503862A (ja) | Ｃｄ８＋ ｔ細胞の誘導のための組成物および方法 | |
| KR20170015286A (ko) | Th17 세포의 유도를 위한 조성물 및 방법 | |
| JP2003535903A (ja) | プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物 | |
| HK1204008A1 (en) | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells | |
| KR20230124601A (ko) | 이식편대숙주병을 치료하기 위한 설계된 박테리아 조성물 | |
| CN111886333A (zh) | 诱导cd8+t细胞的组合物和方法 | |
| US11725183B2 (en) | Method of culturing segmented filamentous bacteria in vitro | |
| TW202146035A (zh) | 用於降低細胞介素表現之組成物及方法 | |
| Joo et al. | Critical role of TSLP-responsive mucosal dendritic cells in the induction of nasal antigen-specific IgA response | |
| Gionchetti et al. | Probiotics for the treatment of postoperative complications following intestinal surgery | |
| KR20030016298A (ko) | 칸디다증의 치료를 위한 조성물 및 방법 | |
| JP7040701B2 (ja) | 抗がん腫瘍溶解性ウイルス併用療法および優良レスポンダー選択プラットフォーム | |
| Gionchetti et al. | VSL# 3: an analysis of basic and clinical contributions in probiotic therapeutics | |
| US11090357B2 (en) | Bioengineered lactobacillus probiotics and the uses thereof | |
| CN114574405B (zh) | 植物乳杆菌菌株wka86及其在制备防治口臭制品方面的用途与制品 | |
| AU2001265694B2 (en) | Compositions and methods for treatment of candidiasis | |
| CN103987839A (zh) | 能够抑制幽门螺杆菌菌株粘附至上皮细胞的新德式乳杆菌保加利亚亚种菌株 | |
| JP6483098B2 (ja) | クラミジア感染症予防治療剤 | |
| US9827319B2 (en) | Combined therapy and prophylaxis for genital tract infections | |
| AU2001265694A1 (en) | Compositions and methods for treatment of candidiasis | |
| Elahi et al. | Development of surrogate markers for oral immunisation against Candida albicans | |
| Kim et al. | IL-10 deficient mice monoassociated with non-pathogenic Enterococcus faecalis develop chronic colitis | |
| Xu et al. | B, Li N and Xu Z (2020) Mediation of Mucosal Immunoglobulins in Buccal Cavity of Teleost in Antibacterial Immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20021218 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |